Press Release


Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal
Jun 17, 2020 18:00 JST
SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that their COVID-19 research with Global Research and Discovery Group Sciences ("GRDG"), conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc. ("Vilotos"), was published in the peer-reviewed scientific journal Molecules on June 11, 2020.
More info..

Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts
Jun 01, 2020 13:00 JST
SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary, Impact Biomedical Inc., would like to update its stakeholders on its suite of antiviral and medical technologies.
More info..

Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts
Apr 24, 2020 10:00 JST
SGX-listed Singapore eDevelopment Ltd's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced recently that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical's effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million).
More info..

Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak
Mar 18, 2020 11:00 JST
Singapore Exchange-listed Singapore eDevelopment Limited has announced that its wholly-owned U.S. biomedical subsidiary, Impact BioMedical, Inc., has, through its scientific research partner, GRDG Sciences, LLC. ("GRDG"), recently conducted molecular docking studies, utilizing advanced computational models, which indicate Linebacker and Equivir successfully inhibit infection of SARS-CoV-2, the virus responsible for the COVID-19 outbreak.
More info..

Global BioLife to Present 3F Antimicrobial Fragrance at 2020 ASM Biothreats
Nov 15, 2019 02:00 JST
Global BioLife Inc, the U.S.subsidiary of SGX-listed Singapore eDevelopment Ltd (SeD), will present research on its 3F Antimicrobial Fragrance as a new method to prevent and treat Tuberculosis at the 2020 ASM Biothreats conference, taking place from 28 to 30 January 2020 in Arlington, Virginia.
More info..

Global BioLife to present Functional Fragrance Formula at the American Society for Microbiology's Biothreats Conference as a New Method to Prevent and Treat Tuberculosis
Oct 29, 2019 09:00 JST
SGX-listed Singapore eDevelopment Limited ("SeD", SGX:40V) wishes to announce that its biomedical subsidiary incorporated in Nevada, Global BioLife Inc. ("Global BioLife") will be presenting its research on its Functional Fragrance Formula ("3F") against tuberculosis at the 2020 American Society for Microbiology ("ASM") Biothreats Conference.
More info..

Global BioLife unveils naturally modified Laetose at Harvard Global Catalyst Health Summit
Jul 24, 2019 15:00 JST
SGX-listed Singapore eDevelopment Ltd (SeD) is pleased to announce the results of clinical trials conducted on Laetose(TM), developed by its U.S. biomedical subsidiary, Global BioLife Inc. ("Global BioLife").
More info..

Global BioLife's 3F Mosquito Repellent Formula performs well in Independent Testing
Jun 12, 2019 14:00 JST
SGX-listed Singapore eDevelopment Ltd (SeD) wishes to announce that its U.S. biomedical subsidiary Global BioLife Inc. has independently tested its new 3F Mosquito Formula which performs well against mosquitoes for six (6) to eight (8) hours.
More info..

Global BioLife's 3F Antimicrobial Fragrance shows Efficacy against Tuberculosis
Jan 28, 2019 12:00 JST
SGX-listed Singapore eDevelopment Ltd (SeD) is pleased to announce that its U.S. biomedical subsidiary Global BioLife Inc. has developed 3F Antimicrobial Fragrance, which shows efficacy against tuberculosis.
More info..

Singapore eDevelopment's Global BioLife to present Parkinson's Research at Neuroscience 2018
Nov 07, 2018 19:00 JST
Singapore eDevelopment (SGX: 40V) ("SeD") subsidiary, Global BioLife Inc. is pleased to announce that research of their promising drug platform, Linebacker, will be presented at Neuroscience 2018, the Annual Meeting for the International Society for Neuroscience (SfN) in San Diego, California.
More info..

Singapore eDevelopment Limited Announces Corporate and Business Update
Jun 18, 2018 19:00 JST
The Board of Directors of Singapore eDevelopment Limited wishes to provide shareholders an update on the Group's operations.
More info..

Singapore eDevelopment's Global BioLife develops Low Glycemic Modified Sugar
May 31, 2018 18:00 JST
Singapore Exchange-listed Singapore eDevelopment Limited ("SeD") announced today that its U.S. biomedical subsidiary, Global BioLife, Inc. ("Global BioLife"), has developed a low glycemic index, naturally modified sugar - Laetose - which has the potential to affect the world's sugar market.
More info..

Singapore eDevelopment's Global BioLife confirms LB2 efficacy against Ebola
Mar 01, 2018 14:00 JST
Singapore eDevelopment (SGX: 40V; SeD) is pleased to announce biomedical subsidiary Global BioLife, Inc. has completed the initial Zaire Ebola research portion for the study of new anti-viral drug LB2, part of its new universal therapeutic drug platform, Linebacker.
More info..

Singapore eDevelopment's Global BioLife confirms 100% Repellency of 3F Mosquito Fragrance
Nov 01, 2017 18:00 JST
SGX-listed Singapore eDevelopment Ltd (SeD) announced today that its U.S. biomedical subsidiary, Global BioLife Inc. has completed development and testing of mosquito deterring technologies including fragrances, paints, and fabric.
More info..

Singapore eDevelopment's Global BioLife develops Low-GI Modified Sugar
Oct 24, 2017 18:00 JST
SGX-listed Singapore eDevelopment Ltd ("SeD") announced today that its U.S. biomedical subsidiary, Global BioLife Inc. has developed a breakthrough low-calorie, low glycemic index, natural, modified sugar Laetose -- which has the potential to affect the world's sugar market.
More info..

Singapore eDevelopment's Global BioLife and Chemia Corp. to develop 3F suite of Functional Fragrances
Aug 15, 2017 19:00 JST
Singapore eDevelopment Ltd (SeD; SGX:SGE) has announced that its indirect subsidiary, Global BioLife Inc., is collaborating with U.S.-based Chemia Corporation to develop specialised fragrances which can counter mosquito-borne diseases, diminish stress and anxiety, and act in anti-viral medical applications.
More info..

First-Year Performance of Global Systematic Multi-Strategy Fund
Jun 15, 2017 10:15 JST
The Board of Directors of Singapore eDevelopment Ltd ("SeD") wishes to announce that its Global Systematic Multi-Strategy Fund ("GSMS Fund") managed by Hengfai Asset Management Pte Ltd ("HFAM"), a wholly owned subsidiary of SeD's investment-arm SeD Capital Pte Ltd, achieved a gross and net return of 15% and 10%, respectively, in its first year of operation.
More info..

Singapore eDevelopment Subsidiary Initiates Research on New Universal Drug Platform
May 22, 2017 11:00 JST
Singapore eDevelopment Limited ("SeD") subsidiary Global BioLife Inc. has initiated advanced research of a new universal therapeutic drug platform, known as Linebacker, to combat a range of diseases including Alzheimer's, diabetes and cancer.
More info..

Latest Release


More Latest Release >>